Cargando…
Budget impact of intravenous iron therapy with ferric carboxymaltose in patients with chronic heart failure and iron deficiency in Germany
AIMS: Treatment of iron deficiency (ID) in patients with heart failure (HF) with intravenous iron substitution [ferric carboxymaltose (FCM)] has previously shown significant improvements in exercise capacity, New York Heart Association (NYHA) functional class, quality of life, and reduction of hospi...
Autores principales: | , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
John Wiley and Sons Inc.
2017
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5542731/ https://www.ncbi.nlm.nih.gov/pubmed/28772041 http://dx.doi.org/10.1002/ehf2.12179 |
_version_ | 1783255047193231360 |
---|---|
author | Theidel, Ulrike Väätäinen, Saku Martikainen, Janne Soini, Erkki Hardt, Thomas Doehner, Wolfram |
author_facet | Theidel, Ulrike Väätäinen, Saku Martikainen, Janne Soini, Erkki Hardt, Thomas Doehner, Wolfram |
author_sort | Theidel, Ulrike |
collection | PubMed |
description | AIMS: Treatment of iron deficiency (ID) in patients with heart failure (HF) with intravenous iron substitution [ferric carboxymaltose (FCM)] has previously shown significant improvements in exercise capacity, New York Heart Association (NYHA) functional class, quality of life, and reduction of hospitalization. The aim of this study was to estimate the budget impact of FCM treatment for patients with HF and ID. METHODS AND RESULTS: Individual patient data from four double‐blind randomized controlled trials were pooled for this analysis. Expected outcomes were modelled for a treatment period of 1 year, using multivariate statistical methods. Associated unit costs were derived from claims data. Budget impact was calculated from the perspective of the Statutory Health Insurance. Multiple deterministic sensitivity analyses were performed. The annual budget impact for therapy with FCM vs. no‐iron therapy was €2 735 505 and €2 695 474 for 1000 patients, respectively, resulting in additional annual costs of €40.03 for each treated patient. Main costs drivers are the FCM treatment cost and cost of hospitalizations due to HF worsening. FCM therapy compared with no‐iron therapy resulted in reduced cost per 1000 patients: for reduced hospitalization due to HF worsening (52 vs. 129 hospitalizations amounting to €230 591 vs. €597 078), for reduced other medication (€1 611 007 vs. €1 679 908), fewer outpatient visits (€332 523 vs. €378 019), and home visits (€29 627 vs. €40 469). Sensitivity analyses showed robustness of the results. CONCLUSIONS: Therapy with FCM has a minimal budget impact of €40 031 per 1000 patients per year. This budget impact translates into reduced and shorter hospitalizations and improved symptomatic status of the patients. |
format | Online Article Text |
id | pubmed-5542731 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2017 |
publisher | John Wiley and Sons Inc. |
record_format | MEDLINE/PubMed |
spelling | pubmed-55427312017-08-17 Budget impact of intravenous iron therapy with ferric carboxymaltose in patients with chronic heart failure and iron deficiency in Germany Theidel, Ulrike Väätäinen, Saku Martikainen, Janne Soini, Erkki Hardt, Thomas Doehner, Wolfram ESC Heart Fail Original Research Articles AIMS: Treatment of iron deficiency (ID) in patients with heart failure (HF) with intravenous iron substitution [ferric carboxymaltose (FCM)] has previously shown significant improvements in exercise capacity, New York Heart Association (NYHA) functional class, quality of life, and reduction of hospitalization. The aim of this study was to estimate the budget impact of FCM treatment for patients with HF and ID. METHODS AND RESULTS: Individual patient data from four double‐blind randomized controlled trials were pooled for this analysis. Expected outcomes were modelled for a treatment period of 1 year, using multivariate statistical methods. Associated unit costs were derived from claims data. Budget impact was calculated from the perspective of the Statutory Health Insurance. Multiple deterministic sensitivity analyses were performed. The annual budget impact for therapy with FCM vs. no‐iron therapy was €2 735 505 and €2 695 474 for 1000 patients, respectively, resulting in additional annual costs of €40.03 for each treated patient. Main costs drivers are the FCM treatment cost and cost of hospitalizations due to HF worsening. FCM therapy compared with no‐iron therapy resulted in reduced cost per 1000 patients: for reduced hospitalization due to HF worsening (52 vs. 129 hospitalizations amounting to €230 591 vs. €597 078), for reduced other medication (€1 611 007 vs. €1 679 908), fewer outpatient visits (€332 523 vs. €378 019), and home visits (€29 627 vs. €40 469). Sensitivity analyses showed robustness of the results. CONCLUSIONS: Therapy with FCM has a minimal budget impact of €40 031 per 1000 patients per year. This budget impact translates into reduced and shorter hospitalizations and improved symptomatic status of the patients. John Wiley and Sons Inc. 2017-07-03 /pmc/articles/PMC5542731/ /pubmed/28772041 http://dx.doi.org/10.1002/ehf2.12179 Text en © 2017 The Authors. ESC Heart Failure published by John Wiley & Sons Ltd on behalf of the European Society of Cardiology. This is an open access article under the terms of the Creative Commons Attribution (http://creativecommons.org/licenses/by/4.0/) License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited. |
spellingShingle | Original Research Articles Theidel, Ulrike Väätäinen, Saku Martikainen, Janne Soini, Erkki Hardt, Thomas Doehner, Wolfram Budget impact of intravenous iron therapy with ferric carboxymaltose in patients with chronic heart failure and iron deficiency in Germany |
title | Budget impact of intravenous iron therapy with ferric carboxymaltose in patients with chronic heart failure and iron deficiency in Germany |
title_full | Budget impact of intravenous iron therapy with ferric carboxymaltose in patients with chronic heart failure and iron deficiency in Germany |
title_fullStr | Budget impact of intravenous iron therapy with ferric carboxymaltose in patients with chronic heart failure and iron deficiency in Germany |
title_full_unstemmed | Budget impact of intravenous iron therapy with ferric carboxymaltose in patients with chronic heart failure and iron deficiency in Germany |
title_short | Budget impact of intravenous iron therapy with ferric carboxymaltose in patients with chronic heart failure and iron deficiency in Germany |
title_sort | budget impact of intravenous iron therapy with ferric carboxymaltose in patients with chronic heart failure and iron deficiency in germany |
topic | Original Research Articles |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5542731/ https://www.ncbi.nlm.nih.gov/pubmed/28772041 http://dx.doi.org/10.1002/ehf2.12179 |
work_keys_str_mv | AT theidelulrike budgetimpactofintravenousirontherapywithferriccarboxymaltoseinpatientswithchronicheartfailureandirondeficiencyingermany AT vaatainensaku budgetimpactofintravenousirontherapywithferriccarboxymaltoseinpatientswithchronicheartfailureandirondeficiencyingermany AT martikainenjanne budgetimpactofintravenousirontherapywithferriccarboxymaltoseinpatientswithchronicheartfailureandirondeficiencyingermany AT soinierkki budgetimpactofintravenousirontherapywithferriccarboxymaltoseinpatientswithchronicheartfailureandirondeficiencyingermany AT hardtthomas budgetimpactofintravenousirontherapywithferriccarboxymaltoseinpatientswithchronicheartfailureandirondeficiencyingermany AT doehnerwolfram budgetimpactofintravenousirontherapywithferriccarboxymaltoseinpatientswithchronicheartfailureandirondeficiencyingermany |